Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Track PRAX with free AI briefings, catalyst countdowns, and dilution alerts.

PRAX · Praxis Precision Medicines, Inc.

Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.

$1.7B Cash on Hand
62.9mo Cash Runway
Follow PRAX by email Get an email when PRAX reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.

We send one confirmation email first. Only emails about PRAX, unsubscribe in one click. Privacy

💊 Upcoming FDA Decisions

PDUFA DateDrugIndicationTypePoAOptions-implied move
2026-12-27 relutrigine SCN2A/SCN8A developmental epileptic encephalopathy NDA 61% ±32% by Jan 15
2027-01-29 ulixacaltamide essential tremor NDA 66% ±41% by Feb 19

Options-implied move = price of the at-the-money straddle for the first option expiry after the PDUFA date, as a share of the stock price (Yahoo Finance quotes, Nov 17). It prices every move until that expiry, not only the FDA decision.

PoA = estimated probability of approval: base rates calibrated against BioRadar's verified FDA outcomes, adjusted for application type, modality, therapy area, cash runway and problems the FDA has raised with the application, as the company has disclosed them. Not investment advice. See the full PDUFA calendar →

📣 What PRAX Says Is Next

Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.

📄 Latest SEC Filings in Plain English

Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.

🧪 Trial & FDA Catalysts

📊 Drug Pipeline

DrugIndicationMost advanced trialStatus
vormatrogine Epilepsy, Tonic-Clonic Phase 3 · NCT07287163 Enrolling by invitation
PRAX-562 SCN2A Encephalopathy Phase 2/3 · NCT05818553 Active not recruiting
PRAX-114 Major Depressive Disorder Phase 2/3 · NCT04832425 Completed
Nimotuzumab Pancreatic Cancer, Advanced or Metastatic Phase 2/3 · NCT00561990 Completed
Relutrigine Developmental and Epileptic Encephalopathy 1 Phase 3 · NCT07010471 Active not recruiting
PRAX-222 - Optional Ascending Doses SCN2A-DEE Phase 1/2 · NCT05737784 Active not recruiting
PRAX-222 - Initial Dose SCN2A-DEE Phase 1/2 · NCT05737784 Active not recruiting
PRAX-222 - Initial Ascending Doses SCN2A-DEE Phase 1/2 · NCT05737784 Active not recruiting
PRAX-222 - Fixed Doses SCN2A-DEE Phase 1/2 · NCT05737784 Active not recruiting
Part B: 120 mg PRAX-944 Essential Tremor Phase 2 · NCT05021978 Completed
Part A: 20 and 40 mg PRAX-944 Essential Tremor Phase 2 · NCT05021978 Completed
Flexibly dosed 20 mg to 100 mg PRAX-944 Essential Tremor Phase 2 · NCT05021991 Completed
PRAX-628 Healthy Phase 1 · NCT06840925 Completed
PRX-P4-003 Healthy Early Phase 1 · NCT04638803 Completed
Fencamfamin Hydrochloride Healthy Early Phase 1 · NCT04638803 Completed

Also used in these trials (approved or third-party drugs, not PRAX's own candidates): Atomoxetine.

Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it

💰 Cash Runway & Dilution Risk

PRAX holds $1.7B in cash and short-term investments (as of Sep 30, 2026) and burns about $79.6M/quarter from operations, an estimated runway of 62.9 months at that rate (BioRadar estimate, not company guidance).

Dilution pressure: 42 · Elevated

Recent financing filings on SEC EDGAR:

Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when PRAX files for a raise →

👥 Who Owns PRAX

Insiders 8% Other 5%+ holders 5.6% Institutions (467 holders) 86.4% Public and other holders 0%
HolderTypeShares% of sharesAs of
FMR LLC Institution (13G, 5%+) 2,565,828 9.18% 2026-09-30
Adage Capital Management, L.P.
10% owner
Insider 2,060,175 7.37% 2025-10-16
Perceptive Advisors LLC Institution (13G, 5%+) 1,995,986 7.14% 2025-12-31
Baker Bros. Advisors LP Institution (13G, 5%+) 1,753,198 6.27% 2026-03-31
Steven A. Cohen 5%+ holder (13G) 1,569,309 5.61% 2025-12-31
Vanguard Capital Management Institution (13G, 5%+) 1,419,323 5.08% 2026-03-31
Marcio Souza
Chief Executive Officer, Director · +22,110 options
Insider 56,495 0.20% 2026-07-08
Timothy Edwin Kelly
Chief Financial Officer · +7,040 options
Insider 31,167 0.11% 2026-05-14
Megan Sniecinski
Chief Operating Officer · +7,700 options
Insider 28,664 0.10% 2026-05-14
Alex Nemiroff
General Counsel and Secretary · +27,564 options
Insider 26,011 0.09% 2026-05-14
Dean J Mitchell
Director · +9,415 options
Insider 18,622 0.07% 2026-06-10
Lauren Mastrocola
Principal Accounting Officer · +29,177 options
Insider 13,573 0.05% 2026-05-14

Share count 27,951,553 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.

📅 Past FDA Decisions & Stock Reactions

DateDrugTypeRun-up 30dDecision 1dAfter 5d
2025-12-31 — NDA +51.2% -0.8% -1.5%

Browse all historical PDUFA outcomes →

Get the full PRAX picture

The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for PRAX and every other ticker you follow. Card required, cancel anytime.

Start 7-day free trial →

Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.